Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1831 in immunoglobulin G4-related disease
jRCT2043250165Phase 2Recruiting
- Sponsor
- Acepodia
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label trial of ACE1831 in IgG4-related disease (IgG4-RD) (4 cohorts), sponsored by Acepodia. Primary endpoints: Incidence of adverse events, Clinically significant laboratory changes and 3 more. Started Jan 2026; status: recruiting.
02
Drugs
ACE1831
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on jRCT2043250165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043250165.